Zydus Cadila gets USFDA nod to market its cancer treatment injection
Drug firm Zydus Cadila said it has received final nod from USFDA to market its generic Doxorubicin Hydrochloride Liposome injection, used for treatment of certain types of cancer, in the US CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives its first complex injectable approval from USFDA for Doxorubicin Hydrochloride Liposome Injection. CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificates
Zydus Cadila gets tentative approval for generic diabetes drug
The drug is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
'Zydus Cadila receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets' CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
'Zydus Cadila receives final approval from the USFDA to market Midodrine Hydrochloride Tablets'
Zydus Cadila gets USFDA nod for muscle relaxant injection
Cadila Healthcare says Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP in the strength of 20 mg (base)/10 mL (2 mg/mL) multiple-dose vial CADILA HEALTHCARE LTD. - 532321 - Transcript Of 25Th Annual General Meeting
Transcript of 25th Annual General Meeting CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from the USFDA for Cisatracurium Besylate Injection CADILA HEALTHCARE LTD. - 532321 - Participation In Investor Conference
Participation in Investor Conference